Across TCGA pan-cancer cohorts, LCE1A RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated LCE1A data layer compared with 1 for mutation status.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LCE1A RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LCE1A expression acts as an unfavorable survival marker, although some lineages such as LIHC and HNSC show a favorable association.
BRCA, BLCA, and MESO are the cancer types where LCE1A RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.